A Phase 2 interventional study of ABT-494 in Crohn's Disease (CD), sponsored by AbbVie. Completed at 61 sites in 18 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-13.
Sponsored by AbbVie · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Crohn Disease by AbbVie — 6 open to participants now, 14 under way, 6 of them phase 3. Crohn Disease · AbbVie.
Among the 55 studies in Crohn Disease by AbbVie, this one is the 20th largest by enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2016, is one of 8 in phase 2, and was the 25th registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →6 of the 55 studies in Crohn Disease by AbbVie are open now, in 12 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, Canada, Israel and 2 more countries
Ages 18–75
AbbVie · Sites in Italy
Ages 18+
AbbVie · Sites in Belgium
Ages 18+
AbbVie · Sites in United States, Austria, Belgium and 30 more countries
Ages 18–75
AbbVie · Sites in United States, Belgium, Bulgaria and 18 more countries
Ages 2–17
By country, each count listing its studies:
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 107 is above the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 220 across the 27 interventional studies, 252 across the 26 observational. Of the 38 that completed or were terminated, 28 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
2 of the studies in Crohn Disease by AbbVie that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06063967Phase 3AbbVieA Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. | 2027-03 |
| NCT03345823Phase 3AbbVieA Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 55 studies in Crohn Disease by AbbVie, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a open-label extension (OLE) study designed to evaluate the long-term efficacy, safety, and tolerability of Upadacitinib (ABT-494).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open label dose B QD
Drug: ABT-494
Open label dose A once daily (QD)
Drug: ABT-494
Tablet: Oral
Also known as: Upadacitinib, RINVOQ
Percentage of Participants Achieving Endoscopic Remission at Month 12
Endoscopic remission was based on Simplified Endoscopic Score for Crohn's disease (SES-CD). The SES-CD assessed the size of mucosal ulcers, the ulcerated surface, the endoscopic extension and the presence of stenosis. SES-CD was based on endoscopic findings in 5 bowel segments (Ileum, right colon, transverse colon, left colon/sigmoid, and rectum). Each item was scored 0 to 3 per segment. The sum of the scores for each endoscopic variable ranged from 0 to 15, except for stenosis, where it varied between 0 and 11; total score ranged from 0 to 56. A lower score indicated better outcome. Endoscopic remission was defined as SES-CD ≤4 and at least two-point reduction versus Baseline of Study M13-740 and no subscore \>1 in any individual variable.
Time frame: Month 12
Percentage of Participants Achieving Clinical Remission at Month 12
Clinical remission was defined as average daily stool frequency ≤1.5 and not worse than Baseline and average daily abdominal pain score ≤1.0 and not worse than baseline in Study M13-740. Abdominal pain was assessed using the CDAI component "abdominal pain" rated as none \[0\], mild \[1\], moderate \[2\], and severe \[3\]) (cumulative total over the past 7 days) as per the CDAI to calculate abdominal pain score; total score range from 0 to 105.
Time frame: Month 12
Percentage of Participants Achieving Endoscopic Remission
Endoscopic remission was based on SES-CD. The SES-CD assessed the size of mucosal ulcers, the ulcerated surface, the endoscopic extension and the presence of stenosis. SES-CD was based on endoscopic findings in 5 bowel segments (Ileum, right colon, transverse colon, left colon/sigmoid, and rectum). Each item was scored 0 to 3 per segment. The sum of the scores for each endoscopic variable ranged from 0 to 15, except for stenosis, where it varied between 0 and 11; total score ranged from 0 to 56. A lower score indicated better outcome. Endoscopic remission was defined as SES-CD ≤4 and at least two-point reduction versus Baseline of Study M13-740 and no subscore \>1 in any individual variable. Week 52 visit of Study M13-740 was considered Week 0 (Baseline) of Study M14-327.
Time frame: Week 0 (Baseline), Months 24, 36, 48, 60, 72, 84, and 96
Percentage of Participants Achieving Clinical Remission
Clinical remission was defined as average daily stool frequency ≤1.5 and not worse than baseline and average daily abdominal pain score of ≤1.0 and not worse than baseline of Study M13-740. Abdominal pain was assessed using the CDAI component "abdominal pain" rated as none \[0\], mild \[1\], moderate \[2\], and severe \[3\]) (cumulative total over the past 7 days) and multiplied by a factor of 5 as per the CDAI to calculate abdominal pain score; total score range from 0 to 105.
Time frame: Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96
Percentage of Participants Achieving Modified Clinical Remission
Modified Clinical Remission was defined as average daily stool frequency ≤2.8 and not worse than baseline and average daily abdominal pain score of ≤1.0 and not worse than baseline of Study M13-740, among participants with stool frequency ≥4.0 or abdominal pain score ≥2.0 at Baseline of Study M13-740. Abdominal pain was assessed using the CDAI component "abdominal pain" rated as none \[0\], mild \[1\], moderate \[2\], and severe \[3\]) (cumulative total over the past 7 days) and multiplied by a factor of 5 as per the CDAI to calculate abdominal pain score; total score range from 0 to 105.
Time frame: Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96
Percentage of Participants Achieving Remission
Remission=clinical remission and endoscopic remission. Clinical remission was an average daily stool frequency ≤1.5 and not worse than baseline and average daily abdominal pain score of ≤1.0 and not worse than baseline of Study M13-740. Abdominal pain was assessed by CDAI component "abdominal pain"; rated as none \[0\], mild \[1\], moderate \[2\], severe \[3\]) cumulative total over the past 7 days and multiplied by a factor of 5 as per CDAI. Abdominal pain score range: 0 to 105. Endoscopic remission was based on SES-CD and assessed the size of mucosal ulcers, ulcerated surface, endoscopic extension and presence of stenosis. SES-CD was based on endoscopic findings in 5 bowel segments: Ileum, right colon, transverse colon, left colon/sigmoid, and rectum. Each item was scored 0 to 3 per segment. The sum of the scores for each endoscopic variable ranged from 0 to 15, except for stenosis, where it varied between 0 and 11; total score ranged from 0 to 56. A lower score indicated better outcome.
Time frame: Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96
Percentage of Participants Achieving CDAI Remission
CDAI is a measure of clinical response and remission that includes 8 variables encompassing both participant-reported (symptoms, general well-being) and objective (medication usage, laboratory variables, presence of abdominal mass or complications, and weight) variables. For symptoms scores, participants kept a diary card and the daily symptom scores were summed for the week. Each item in the CDAI was assigned a pre-specified factor to calculate the subtotals, and the subtotals of the items were totaled to produce the CDAI. Higher CDAI scores indicated greater disease activity, with a lower limit of 0 and no set upper limit. Total score range: 0 to 600. CDAI remission was defined as CDAI score \<150.
Time frame: Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96
Percentage of Participants Achieving Inflammatory Bowel Disease Questionnaire (IBDQ) Remission
The IBDQ is a 32-item (ranged 1 to 7) self-report questionnaire for participants with inflammatory bowel disease to evaluate the participant-reported outcomes across 4 dimensions: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). IBDQ total score range: 32 to 224. A higher score indicating better outcome. IBDQ remission was defined as IBDQ score ≥170.
Time frame: Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96
Percentage of Participants Achieving Endoscopic Improvement
Endoscopic improvement was defined as SES-CD at least 50% reduction from Baseline or endoscopic remission. Endoscopic remission was based on SES-CD and assessed the size of mucosal ulcers, ulcerated surface, endoscopic extension and presence of stenosis. SES-CD was based on endoscopic findings in 5 bowel segments: Ileum, right colon, transverse colon, left colon/sigmoid, and rectum. Each item was scored 0 to 3 per segment. The sum of the scores for each endoscopic variable ranged from 0 to 15, except for stenosis, where it varied between 0 and 11; total score ranged from 0 to 56. A lower score indicated better outcome. Endoscopic remission was defined as SES-CD ≤4 and at least 2-point reduction versus baseline of Study M13-740 and no subscore \>1 in any individual variable. Week 52 visit of Study M13-740 was considered Week 0 (Baseline) of Study M14-327.
Time frame: Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96
Percentage of Participants Taking Steroids at Baseline (of Study M13-740) Who Are Steroid-Free at the Specified Timepoint in Study M14-327
Time frame: Months 12, 24, 36, 48, 60, 72, 84, and 96
Percentage of Participants Achieving Remission and Normal C-Reactive Protein (CRP)
Remission = clinical remission and endoscopic remission. Clinical remission was average daily stool frequency ≤1.5 and not worse than baseline and average daily abdominal pain score ≤1.0 and not worse than baseline of Study M13-740. Abdominal pain was assessed by CDAI component "abdominal pain" rated: none \[0\], mild \[1\], moderate \[2\], severe \[3\] cumulative total over the past 7 days and multiplied by a prespecified factor of 5; total score range from 0 to 105. Endoscopic remission was based on SES-CD and assessed size of mucosal ulcers, ulcerated surface, endoscopic extension and presence of stenosis. SES-CD was based on endoscopic findings in 5 bowel segments: Ileum, right colon, transverse colon, left colon/sigmoid, and rectum; scored 0 to 3 per segment. Sum of scores for each endoscopic variable ranged from 0 to 15, except for stenosis, where it varied between 0 and 11; total score ranged from 0 to 56. A lower score indicated better outcome. Normal CRP=high-sensitivity CRP \<5 mg/L.
Time frame: Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96
Percentage of Participants in Remission at Week 0 Who Maintained Remission
Remission=clinical remission and endoscopic remission. Clinical remission was an average daily stool frequency ≤1.5 and not worse than baseline and average daily abdominal pain score of ≤1.0 and not worse than baseline of Study M13-740. Abdominal pain was assessed by CDAI component "abdominal pain"; rated as none \[0\], mild \[1\], moderate \[2\], severe \[3\]) cumulative total over the past 7 days and multiplied by a factor of 5 as per CDAI. Abdominal pain score range: 0 to 105. Endoscopic remission was based on SES-CD and assessed the size of mucosal ulcers, ulcerated surface, endoscopic extension and presence of stenosis. SES-CD was based on endoscopic findings in 5 bowel segments: Ileum, right colon, transverse colon, left colon/sigmoid, and rectum. Each item was scored 0 to 3 per segment. The sum of the scores for each endoscopic variable ranged from 0 to 15, except for stenosis, where it varied between 0 and 11; total score ranged from 0 to 56. A lower score indicated better outcome.
Time frame: Months 12, 24, 36, 48, 60, 72, 84, and 96
Percentage of Participants in Endoscopic Remission at Week 0 Who Maintained Endoscopic Remission
Endoscopic remission was based on SES-CD and assessed the size of mucosal ulcers, ulcerated surface, endoscopic extension and presence of stenosis. SES-CD was based on endoscopic findings in 5 bowel segments: Ileum, right colon, transverse colon, left colon/sigmoid, and rectum. Each item was scored 0 to 3 per segment. The sum of the scores for each endoscopic variable ranged from 0 to 15, except for stenosis, where it varied between 0 and 11; total score ranged from 0 to 56. A lower score indicated better outcome. Endoscopic remission was defined as SES-CD ≤4 and at least 2-point reduction versus baseline of Study M13-740 and no subscore \>1 in any individual variable. Week 52 visit of Study M13-740 was considered Week 0 (Baseline) of Study M14-327.
Time frame: Months 12, 24, 36, 48, 60, 72, 84, and 96
Percentage of Participants Achieving Response
Response = clinical and endoscopic response. Clinical response was average daily stool frequency at least 30% reduction from baseline and average daily abdominal pain score not worse than baseline or average daily abdominal pain at least 30% reduction from baseline of Study M13-740 and average daily stool frequency not worse than baseline of Study M13-740. Abdominal pain based on CDAI component "abdominal pain" rated none \[0\], mild \[1\], moderate \[2\], severe \[3\] cumulative total over past 7 days and multiplied by prespecified factor of 5; total score range from 0-105. Endoscopic response was decrease ≥25% SES-CD from baseline of Study M13-740. SES-CD was based on endoscopic findings in 5 bowel segments (Ileum, right colon, transverse colon, left colon/sigmoid, rectum), scored 0 to 3 per each segment. Sum of the scores for each endoscopic variable ranged from 0-15, except for stenosis, where it varied between 0-11; total score ranged from 0-56. Lower score indicated better outcome.
Time frame: Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96
Percentage of Participants Achieving Enhanced Clinical Response
Enhanced Clinical Response was defined as average daily stool frequency at least 65% reduction from baseline and average daily abdominal pain score not worse than baseline or average daily abdominal pain score at least 35% reduction from baseline of Study M13-740 and average daily stool frequency not worse than baseline of Study M13-740.Abdominal pain was assessed by CDAI component "abdominal pain" rated none \[0\], mild \[1\], moderate \[2\], severe \[3\]; cumulative total over the past 7 days) and multiplied by prespecified factor of 5; total score range from 0 to 105.
Time frame: Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96
Percentage of Participants Achieving Clinical Response
Clinical response was defined as average daily stool frequency at least 30% reduction from Baseline and average daily abdominal pain score not worse than Baseline or average daily abdominal pain score at least 30% reduction from baseline of Study M13-740 and average daily stool frequency not worse than baseline of Study M13-740. Abdominal pain was assessed by CDAI component "abdominal pain" rated none \[0\], mild \[1\], moderate \[2\], severe \[3\]; cumulative total over the past 7 days) and multiplied by prespecified factor of 5; total score range from 0 to 105.
Time frame: Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96
Percentage of Participants Achieving CDAI Response
CDAI is a measure of clinical response and remission that includes 8 variables encompassing both participant-reported (symptoms, general well-being) and objective (medication usage, laboratory variables, presence of abdominal mass or complications, and weight) variables. For symptoms scores, participants kept a diary card and the daily symptom scores were summed for the week. Each item in the CDAI was assigned a prespecified factor to calculate the subtotals, and the subtotals of the items were totaled to produce the CDAI. Higher scores indicated greater disease activity, with a lower limit of 0 and no set upper limit. Total score range: 0 to 600. CDAI response was defined as a reduction in CDAI scores by ≥70 from baseline of Study M13-740.
Time frame: Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96
Percentage of Participants Achieving Enhanced CDAI Response
CDAI is a measure of clinical response and remission that includes 8 variables encompassing both participant-reported (symptoms, general well-being) and objective (medication usage, laboratory variables, presence of abdominal mass or complications, and weight) variables. For symptoms scores, participants kept a diary card and the daily symptom scores were summed for the week. Each item in the CDAI was assigned a prespecified factor to calculate the subtotals, and the subtotals of the items were totaled to produce the CDAI. Higher scores indicated greater disease activity, with a lower limit of 0 and no set upper limit. Total score range: 0 to 600. Enhanced CDAI response was defined as reduction in CDAI score by ≥100 from baseline of Study M13-740.
Time frame: Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96
Percentage of Participants Achieving Endoscopic Response
Endoscopic response was defined as decrease ≥ 25% SES-CD from Baseline of Study M13-740. SES-CD was based on endoscopic findings in 5 bowel segments (Ileum, right colon, transverse colon, left colon/sigmoid, and rectum). Each item was scored 0 to 3 per segment. The sum of the scores for each endoscopic variable ranged from 0 to 15, except for stenosis, where it varied between 0 and 11; total score ranged from 0 to 56. A lower score indicated better outcome.
Time frame: Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96
Percentage of Participants Achieving IBDQ Response
The IBDQ is a 32-item (ranged 1 to 7) self-report questionnaire for participants with inflammatory bowel disease to evaluate the participant-reported outcomes across 4 dimensions: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). IBDQ total Score range 32 to 224. A higher score indicated better outcome. IBDQ response was defined as an increase in IBDQ score ≥16 point from baseline of Study M13-740.
Time frame: Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96
Percentage of Participants Taking Steroids at Baseline (of Study M13-740) Who Are Steroid-Free for At Least 90 Days and Achieve Remission
Remission = clinical remission and endoscopic remission. Clinical remission was average daily stool frequency ≤1.5, not worse than baseline, and average daily abdominal pain score ≤1.0 and not worse than baseline of Study M13-740. Abdominal pain was assessed using the CDAI component "abdominal pain" rated none \[0\], mild \[1\], moderate \[2\], severe \[3\] (cumulative total over the past 7 days) and multiplied by a factor of 5 as per the CDAI. Total score range 0 to 105. Endoscopic remission was defined as SES-CD ≤4 and at least 2- point reduction versus baseline of Study M13-740 and no subscore \>1 in any individual variable. SES-CD was based on endoscopic findings in 5 segments (Ileum, right colon, transverse colon, left colon/sigmoid, and rectum). Each item was scored 0 to 3 per segment. The sum of the scores for each endoscopic variable ranged from 0 to 15, except for stenosis, where it varied between 0 and 11; total score ranged from 0 to 56. A lower score indicated better outcome
Time frame: Months 12, 24, 36, 48, 60, 72, 84, and 96
Change From Baseline in Fecal Calprotectin Levels
Stool samples were collected for analysis of fecal calprotectin levels.
Time frame: Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96
Change From Baseline in Hs-CRP Levels
Time frame: Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96
Change From Baseline in IBDQ Total Score
The IBDQ is a 32-item (ranged 1 to 7) self-report questionnaire for participants with inflammatory bowel disease to evaluate the participant-reported outcomes across 4 dimensions: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). IBDQ total score range from 32 to 224. A higher score indicated better outcome.
Time frame: Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96
Change From Baseline in SES-CD
The SES-CD assessed the size of mucosal ulcers, the ulcerated surface, the endoscopic extension and the presence of stenosis. SES-CD was based on endoscopic findings in 5 bowel segments (Ileum, right colon, transverse colon, left colon/sigmoid, and rectum). Each item was scored 0 to 3 per segment. The sum of the scores for each endoscopic variable ranged from 0 to 15, except for stenosis, where it varied between 0 and 11; total score ranged from 0 to 56. A lower score indicated better outcome. Endoscopic remission was defined as SES-CD ≤4 and at least two-point reduction versus Baseline of Study M13-740 and no subscore \>1 in any individual variable.
Time frame: Week 0 (Baseline), Months 12, 24, 36, 48, 60, 72, 84, and 96
| Milestone | Upadacitinib 30 mg | Upadacitinib 15 mg, Then 30 mg | Upadacitinib 15 mg |
|---|---|---|---|
| Started | 31 | 29 | 47 |
| Received at least 1 dose of study drug | 31 | 29 | 47 |
| Completed | 10 | 4 | 16 |
| Not completed | 21 | 25 | 31 |
| Withdrew: Adverse event | 8 | 3 | 6 |
| Withdrew: Withdrawal by subject | 7 | 2 | 10 |
| Withdrew: Lost to follow-up | 1 | 0 | 3 |
| Withdrew: Lack of efficacy | 4 | 12 | 9 |
| Withdrew: Required alternative (or prohibited) therapy | 0 | 3 | 1 |
| Withdrew: Participant non-compliance | 1 | 4 | 1 |
| Withdrew: Other, not specified | 0 | 1 | 1 |
Endoscopic remission was based on Simplified Endoscopic Score for Crohn's disease (SES-CD). The SES-CD assessed the size of mucosal ulcers, the ulcerated surface, the endoscopic extension and the presence of stenosis. SES-CD was based on endoscopic findings in 5 bowel segments (Ileum, right colon, transverse colon, left colon/sigmoid, and rectum). Each item was scored 0 to 3 per segment. The sum of the scores for each endoscopic variable ranged from 0 to 15, except for stenosis, where it varied between 0 and 11; total score ranged from 0 to 56. A lower score indicated better outcome. Endoscopic remission was defined as SES-CD ≤4 and at least two-point reduction versus Baseline of Study M13-740 and no subscore \>1 in any individual variable.
| percentage of participants | Upadacitinib 30 mg | Upadacitinib 15 mg, Then 30 mg | Upadacitinib 15 mg |
|---|---|---|---|
| Percentage of Participants Achieving Endoscopic Remission at Month 12 | 54.5 | 54.5 | 46.9 |
Clinical remission was defined as average daily stool frequency ≤1.5 and not worse than Baseline and average daily abdominal pain score ≤1.0 and not worse than baseline in Study M13-740. Abdominal pain was assessed using the CDAI component "abdominal pain" rated as none \[0\], mild \[1\], moderate \[2\], and severe \[3\]) (cumulative total over the past 7 days) as per the CDAI to calculate abdominal pain score; total score range from 0 to 105.
| percentage of participants | Upadacitinib 30 mg | Upadacitinib 15 mg, Then 30 mg | Upadacitinib 15 mg |
|---|---|---|---|
| Percentage of Participants Achieving Clinical Remission at Month 12 | 45.2 | 55.2 | 51.1 |
Endoscopic remission was based on SES-CD. The SES-CD assessed the size of mucosal ulcers, the ulcerated surface, the endoscopic extension and the presence of stenosis. SES-CD was based on endoscopic findings in 5 bowel segments (Ileum, right colon, transverse colon, left colon/sigmoid, and rectum). Each item was scored 0 to 3 per segment. The sum of the scores for each endoscopic variable ranged from 0 to 15, except for stenosis, where it varied between 0 and 11; total score ranged from 0 to 56. A lower score indicated better outcome. Endoscopic remission was defined as SES-CD ≤4 and at least two-point reduction versus Baseline of Study M13-740 and no subscore \>1 in any individual variable. Week 52 visit of Study M13-740 was considered Week 0 (Baseline) of Study M14-327.
| percentage of participants | Upadacitinib 30 mg | Upadacitinib 15 mg, Then 30 mg | Upadacitinib 15 mg |
|---|---|---|---|
| Week 0 | 25.0 | 23.1 | 32.6 |
| Month 24 | 53.3 | 30.8 | 54.2 |
| Month 36 | 50.0 | 60.0 | 58.3 |
| Month 48 | 70.0 | 40.0 | 56.3 |
| Month 60 | 50.0 | 80.0 | 80.0 |
| Month 72 | 55.6 | 42.9 | 53.3 |
| Month 84 | 90.0 | 40.0 | 71.4 |
| Month 96 | 57.1 | 66.7 | 76.9 |
Clinical remission was defined as average daily stool frequency ≤1.5 and not worse than baseline and average daily abdominal pain score of ≤1.0 and not worse than baseline of Study M13-740. Abdominal pain was assessed using the CDAI component "abdominal pain" rated as none \[0\], mild \[1\], moderate \[2\], and severe \[3\]) (cumulative total over the past 7 days) and multiplied by a factor of 5 as per the CDAI to calculate abdominal pain score; total score range from 0 to 105.
| percentage of participants | Upadacitinib 30 mg | Upadacitinib 15 mg, Then 30 mg | Upadacitinib 15 mg |
|---|---|---|---|
| Week 0 | 35.5 | 44.8 | 40.4 |
| Month 24 | 38.7 | 44.8 | 44.7 |
| Month 36 | 45.2 | 44.8 | 42.6 |
| Month 48 | 41.9 | 41.4 | 42.6 |
| Month 60 | 41.9 | 37.9 | 42.6 |
| Month 72 | 41.9 | 37.9 | 40.4 |
| Month 84 | 41.9 | 37.9 | 42.6 |
| Month 96 | 41.9 | 31.0 | 42.6 |
Modified Clinical Remission was defined as average daily stool frequency ≤2.8 and not worse than baseline and average daily abdominal pain score of ≤1.0 and not worse than baseline of Study M13-740, among participants with stool frequency ≥4.0 or abdominal pain score ≥2.0 at Baseline of Study M13-740. Abdominal pain was assessed using the CDAI component "abdominal pain" rated as none \[0\], mild \[1\], moderate \[2\], and severe \[3\]) (cumulative total over the past 7 days) and multiplied by a factor of 5 as per the CDAI to calculate abdominal pain score; total score range from 0 to 105.
| percentage of participants | Upadacitinib 30 mg | Upadacitinib 15 mg, Then 30 mg | Upadacitinib 15 mg |
|---|---|---|---|
| Week 0 | 57.1 | 53.8 | 57.8 |
| Month 12 | 57.1 | 61.5 | 57.8 |
| Month 24 | 50.0 | 57.7 | 55.6 |
| Month 36 | 53.6 | 57.7 | 53.3 |
| Month 48 | 53.6 | 61.5 | 53.3 |
| Month 60 | 53.6 | 50.0 | 53.3 |
| Month 72 | 53.6 | 53.8 | 57.8 |
| Month 84 | 53.6 | 53.8 | 57.8 |
| Month 96 | 53.6 | 50.0 | 57.8 |
Remission=clinical remission and endoscopic remission. Clinical remission was an average daily stool frequency ≤1.5 and not worse than baseline and average daily abdominal pain score of ≤1.0 and not worse than baseline of Study M13-740. Abdominal pain was assessed by CDAI component "abdominal pain"; rated as none \[0\], mild \[1\], moderate \[2\], severe \[3\]) cumulative total over the past 7 days and multiplied by a factor of 5 as per CDAI. Abdominal pain score range: 0 to 105. Endoscopic remission was based on SES-CD and assessed the size of mucosal ulcers, ulcerated surface, endoscopic extension and presence of stenosis. SES-CD was based on endoscopic findings in 5 bowel segments: Ileum, right colon, transverse colon, left colon/sigmoid, and rectum. Each item was scored 0 to 3 per segment. The sum of the scores for each endoscopic variable ranged from 0 to 15, except for stenosis, where it varied between 0 and 11; total score ranged from 0 to 56. A lower score indicated better outcome.
| percentage of participants | Upadacitinib 30 mg | Upadacitinib 15 mg, Then 30 mg | Upadacitinib 15 mg |
|---|---|---|---|
| Week 0 | 14.3 | 15.4 | 14.0 |
| Month 12 | 33.3 | 33.3 | 33.3 |
| Month 24 | 42.9 | 0 | 38.1 |
| Month 36 | 66.7 | 37.5 | 47.8 |
| Month 48 | 62.5 | 22.2 | 46.2 |
| Month 60 | 50.0 | 40.0 | 61.5 |
| Month 72 | 55.6 | 25.0 | 40.0 |
| Month 84 | 75.0 | 25.0 | 66.7 |
| Month 96 | 57.1 | 33.3 | 70.0 |
CDAI is a measure of clinical response and remission that includes 8 variables encompassing both participant-reported (symptoms, general well-being) and objective (medication usage, laboratory variables, presence of abdominal mass or complications, and weight) variables. For symptoms scores, participants kept a diary card and the daily symptom scores were summed for the week. Each item in the CDAI was assigned a pre-specified factor to calculate the subtotals, and the subtotals of the items were totaled to produce the CDAI. Higher CDAI scores indicated greater disease activity, with a lower limit of 0 and no set upper limit. Total score range: 0 to 600. CDAI remission was defined as CDAI score \<150.
| percentage of participants | Upadacitinib 30 mg | Upadacitinib 15 mg, Then 30 mg | Upadacitinib 15 mg |
|---|---|---|---|
| Week 0 | 64.5 | 58.6 | 68.1 |
| Month 12 | 61.3 | 62.1 | 59.6 |
| Month 24 | 54.8 | 44.8 | 57.4 |
| Month 36 | 61.3 | 41.4 | 57.4 |
| Month 48 | 61.3 | 37.9 | 55.3 |
| Month 60 | 58.1 | 37.9 | 57.4 |
| Month 72 | 61.3 | 41.4 | 55.3 |
| Month 84 | 61.3 | 41.4 | 57.4 |
| Month 96 | 58.1 | 37.9 | 57.4 |
The IBDQ is a 32-item (ranged 1 to 7) self-report questionnaire for participants with inflammatory bowel disease to evaluate the participant-reported outcomes across 4 dimensions: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). IBDQ total score range: 32 to 224. A higher score indicating better outcome. IBDQ remission was defined as IBDQ score ≥170.
| percentage of participants | Upadacitinib 30 mg | Upadacitinib 15 mg, Then 30 mg | Upadacitinib 15 mg |
|---|---|---|---|
| Week 0 | 53.6 | 51.7 | 59.6 |
| Month 12 | 56.5 | 40.0 | 72.2 |
| Month 24 | 58.8 | 70.0 | 70.0 |
| Month 36 | 90.9 | 58.3 | 79.2 |
| Month 48 | 83.3 | 63.6 | 90.0 |
| Month 60 | 66.7 | 60.0 | 89.5 |
| Month 72 | 66.7 | 71.4 | 93.8 |
| Month 84 | 54.5 | 60.0 | 92.9 |
| Month 96 | 77.8 | 75.0 | 93.3 |
Endoscopic improvement was defined as SES-CD at least 50% reduction from Baseline or endoscopic remission. Endoscopic remission was based on SES-CD and assessed the size of mucosal ulcers, ulcerated surface, endoscopic extension and presence of stenosis. SES-CD was based on endoscopic findings in 5 bowel segments: Ileum, right colon, transverse colon, left colon/sigmoid, and rectum. Each item was scored 0 to 3 per segment. The sum of the scores for each endoscopic variable ranged from 0 to 15, except for stenosis, where it varied between 0 and 11; total score ranged from 0 to 56. A lower score indicated better outcome. Endoscopic remission was defined as SES-CD ≤4 and at least 2-point reduction versus baseline of Study M13-740 and no subscore \>1 in any individual variable. Week 52 visit of Study M13-740 was considered Week 0 (Baseline) of Study M14-327.
| percentage of participants | Upadacitinib 30 mg | Upadacitinib 15 mg, Then 30 mg | Upadacitinib 15 mg |
|---|---|---|---|
| Week 0 | 57.1 | 50.0 | 65.1 |
| Month 12 | 81.8 | 63.6 | 68.8 |
| Month 24 | 73.3 | 46.2 | 70.8 |
| Month 36 | 90.0 | 70.0 | 70.8 |
| Month 48 | 90.0 | 70.0 | 75.0 |
| Month 60 | 100 | 100 | 86.7 |
| Month 72 | 88.9 | 71.4 | 73.3 |
| Month 84 | 90.0 | 60.0 | 78.6 |
| Month 96 | 100 | 100 | 84.6 |
| percentage of participants | Upadacitinib 30 mg | Upadacitinib 15 mg, Then 30 mg | Upadacitinib 15 mg |
|---|---|---|---|
| Month 12 | 78.6 | 85.7 | 61.5 |
| Month 24 | 64.3 | 57.1 | 53.8 |
| Month 36 | 57.1 | 42.9 | 53.8 |
| Month 48 | 50.0 | 42.9 | 46.2 |
| Month 60 | 42.9 | 35.7 | 38.5 |
| Month 72 | 42.9 | 28.6 | 30.8 |
| Month 84 | 42.9 | 21.4 | 30.8 |
| Month 96 | 0 | 0 | 0 |
Remission = clinical remission and endoscopic remission. Clinical remission was average daily stool frequency ≤1.5 and not worse than baseline and average daily abdominal pain score ≤1.0 and not worse than baseline of Study M13-740. Abdominal pain was assessed by CDAI component "abdominal pain" rated: none \[0\], mild \[1\], moderate \[2\], severe \[3\] cumulative total over the past 7 days and multiplied by a prespecified factor of 5; total score range from 0 to 105. Endoscopic remission was based on SES-CD and assessed size of mucosal ulcers, ulcerated surface, endoscopic extension and presence of stenosis. SES-CD was based on endoscopic findings in 5 bowel segments: Ileum, right colon, transverse colon, left colon/sigmoid, and rectum; scored 0 to 3 per segment. Sum of scores for each endoscopic variable ranged from 0 to 15, except for stenosis, where it varied between 0 and 11; total score ranged from 0 to 56. A lower score indicated better outcome. Normal CRP=high-sensitivity CRP \<5 mg/L.
| percentage of participants | Upadacitinib 30 mg | Upadacitinib 15 mg, Then 30 mg | Upadacitinib 15 mg |
|---|---|---|---|
| Week 0 | 10.7 | 15.4 | 9.3 |
| Month 12 | 28.6 | 30.0 | 30.0 |
| Month 24 | 23.1 | 0 | 23.8 |
| Month 36 | 50.0 | 12.5 | 43.5 |
| Month 48 | 50.0 | 12.5 | 45.5 |
| Month 60 | 50.0 | 25.0 | 53.8 |
| Month 72 | 50.0 | 25.0 | 35.7 |
| Month 84 | 62.5 | 25.0 | 50.0 |
| Month 96 | 42.9 | 33.3 | 50.0 |
Remission=clinical remission and endoscopic remission. Clinical remission was an average daily stool frequency ≤1.5 and not worse than baseline and average daily abdominal pain score of ≤1.0 and not worse than baseline of Study M13-740. Abdominal pain was assessed by CDAI component "abdominal pain"; rated as none \[0\], mild \[1\], moderate \[2\], severe \[3\]) cumulative total over the past 7 days and multiplied by a factor of 5 as per CDAI. Abdominal pain score range: 0 to 105. Endoscopic remission was based on SES-CD and assessed the size of mucosal ulcers, ulcerated surface, endoscopic extension and presence of stenosis. SES-CD was based on endoscopic findings in 5 bowel segments: Ileum, right colon, transverse colon, left colon/sigmoid, and rectum. Each item was scored 0 to 3 per segment. The sum of the scores for each endoscopic variable ranged from 0 to 15, except for stenosis, where it varied between 0 and 11; total score ranged from 0 to 56. A lower score indicated better outcome.
| percentage of participants | Upadacitinib 30 mg | Upadacitinib 15 mg, Then 30 mg | Upadacitinib 15 mg |
|---|---|---|---|
| Month 12 | 100 | 25.0 | 80.0 |
| Month 24 | 66.7 | — | 100 |
| Month 36 | 100 | 100 | 100 |
| Month 48 | 100 | 100 | 100 |
| Month 60 | 100 | 100 | 100 |
| Month 72 | 100 | 100 | 50.0 |
| Month 84 | 100 | 100 | 100 |
| Month 96 | 100 | 50.0 | 100 |
Endoscopic remission was based on SES-CD and assessed the size of mucosal ulcers, ulcerated surface, endoscopic extension and presence of stenosis. SES-CD was based on endoscopic findings in 5 bowel segments: Ileum, right colon, transverse colon, left colon/sigmoid, and rectum. Each item was scored 0 to 3 per segment. The sum of the scores for each endoscopic variable ranged from 0 to 15, except for stenosis, where it varied between 0 and 11; total score ranged from 0 to 56. A lower score indicated better outcome. Endoscopic remission was defined as SES-CD ≤4 and at least 2-point reduction versus baseline of Study M13-740 and no subscore \>1 in any individual variable. Week 52 visit of Study M13-740 was considered Week 0 (Baseline) of Study M14-327.
| percentage of participants | Upadacitinib 30 mg | Upadacitinib 15 mg, Then 30 mg | Upadacitinib 15 mg |
|---|---|---|---|
| Month 12 | 100 | 66.7 | 72.7 |
| Month 24 | 100 | 75.0 | 80.0 |
| Month 36 | 100 | 100 | 80.0 |
| Month 48 | 100 | 100 | 60.0 |
| Month 60 | 100 | 100 | 100 |
| Month 72 | 100 | 66.7 | 75.0 |
| Month 84 | 100 | 100 | 75.0 |
| Month 96 | 100 | 100 | 100 |
Response = clinical and endoscopic response. Clinical response was average daily stool frequency at least 30% reduction from baseline and average daily abdominal pain score not worse than baseline or average daily abdominal pain at least 30% reduction from baseline of Study M13-740 and average daily stool frequency not worse than baseline of Study M13-740. Abdominal pain based on CDAI component "abdominal pain" rated none \[0\], mild \[1\], moderate \[2\], severe \[3\] cumulative total over past 7 days and multiplied by prespecified factor of 5; total score range from 0-105. Endoscopic response was decrease ≥25% SES-CD from baseline of Study M13-740. SES-CD was based on endoscopic findings in 5 bowel segments (Ileum, right colon, transverse colon, left colon/sigmoid, rectum), scored 0 to 3 per each segment. Sum of the scores for each endoscopic variable ranged from 0-15, except for stenosis, where it varied between 0-11; total score ranged from 0-56. Lower score indicated better outcome.
| percentage of participants | Upadacitinib 30 mg | Upadacitinib 15 mg, Then 30 mg | Upadacitinib 15 mg |
|---|---|---|---|
| Week 0 | 67.9 | 53.8 | 72.1 |
| Month 12 | 85.7 | 71.4 | 73.3 |
| Month 24 | 85.7 | 60.0 | 85.7 |
| Month 36 | 100 | 62.5 | 73.9 |
| Month 48 | 87.5 | 66.7 | 76.9 |
| Month 60 | 87.5 | 80.0 | 84.6 |
| Month 72 | 88.9 | 75.0 | 86.7 |
| Month 84 | 87.5 | 75.0 | 75.0 |
| Month 96 | 100 | 100 | 80.0 |
Enhanced Clinical Response was defined as average daily stool frequency at least 65% reduction from baseline and average daily abdominal pain score not worse than baseline or average daily abdominal pain score at least 35% reduction from baseline of Study M13-740 and average daily stool frequency not worse than baseline of Study M13-740.Abdominal pain was assessed by CDAI component "abdominal pain" rated none \[0\], mild \[1\], moderate \[2\], severe \[3\]; cumulative total over the past 7 days) and multiplied by prespecified factor of 5; total score range from 0 to 105.
| percentage of participants | Upadacitinib 30 mg | Upadacitinib 15 mg, Then 30 mg | Upadacitinib 15 mg |
|---|---|---|---|
| Week 0 | 77.4 | 72.4 | 80.9 |
| Month 12 | 74.2 | 69.0 | 80.9 |
| Month 24 | 67.7 | 69.0 | 80.9 |
| Month 36 | 71.0 | 65.5 | 83.0 |
| Month 48 | 71.0 | 69.0 | 83.0 |
| Month 60 | 71.0 | 62.1 | 78.7 |
| Month 72 | 71.0 | 65.5 | 80.9 |
| Month 84 | 71.0 | 65.5 | 78.7 |
| Month 96 | 67.7 | 62.1 | 78.7 |
Clinical response was defined as average daily stool frequency at least 30% reduction from Baseline and average daily abdominal pain score not worse than Baseline or average daily abdominal pain score at least 30% reduction from baseline of Study M13-740 and average daily stool frequency not worse than baseline of Study M13-740. Abdominal pain was assessed by CDAI component "abdominal pain" rated none \[0\], mild \[1\], moderate \[2\], severe \[3\]; cumulative total over the past 7 days) and multiplied by prespecified factor of 5; total score range from 0 to 105.
| percentage of participants | Upadacitinib 30 mg | Upadacitinib 15 mg, Then 30 mg | Upadacitinib 15 mg |
|---|---|---|---|
| Week 0 | 80.6 | 75.9 | 83.0 |
| Month 12 | 74.2 | 75.9 | 85.1 |
| Month 24 | 71.0 | 75.9 | 85.1 |
| Month 36 | 71.0 | 72.4 | 85.1 |
| Month 48 | 71.0 | 79.3 | 85.1 |
| Month 60 | 71.0 | 69.0 | 80.9 |
| Month 72 | 71.0 | 72.4 | 83.0 |
| Month 84 | 71.0 | 72.4 | 80.9 |
| Month 96 | 67.7 | 72.4 | 80.9 |
CDAI is a measure of clinical response and remission that includes 8 variables encompassing both participant-reported (symptoms, general well-being) and objective (medication usage, laboratory variables, presence of abdominal mass or complications, and weight) variables. For symptoms scores, participants kept a diary card and the daily symptom scores were summed for the week. Each item in the CDAI was assigned a prespecified factor to calculate the subtotals, and the subtotals of the items were totaled to produce the CDAI. Higher scores indicated greater disease activity, with a lower limit of 0 and no set upper limit. Total score range: 0 to 600. CDAI response was defined as a reduction in CDAI scores by ≥70 from baseline of Study M13-740.
| percentage of participants | Upadacitinib 30 mg | Upadacitinib 15 mg, Then 30 mg | Upadacitinib 15 mg |
|---|---|---|---|
| Week 0 | 83.9 | 75.9 | 78.7 |
| Month 12 | 77.4 | 82.8 | 78.7 |
| Month 24 | 77.4 | 86.2 | 76.6 |
| Month 36 | 77.4 | 79.3 | 74.5 |
| Month 48 | 77.4 | 82.8 | 68.1 |
| Month 60 | 74.2 | 69.0 | 74.5 |
| Month 72 | 77.4 | 75.9 | 72.3 |
| Month 84 | 77.4 | 75.9 | 72.3 |
| Month 96 | 77.4 | 72.4 | 74.5 |
CDAI is a measure of clinical response and remission that includes 8 variables encompassing both participant-reported (symptoms, general well-being) and objective (medication usage, laboratory variables, presence of abdominal mass or complications, and weight) variables. For symptoms scores, participants kept a diary card and the daily symptom scores were summed for the week. Each item in the CDAI was assigned a prespecified factor to calculate the subtotals, and the subtotals of the items were totaled to produce the CDAI. Higher scores indicated greater disease activity, with a lower limit of 0 and no set upper limit. Total score range: 0 to 600. Enhanced CDAI response was defined as reduction in CDAI score by ≥100 from baseline of Study M13-740.
| percentage of participants | Upadacitinib 30 mg | Upadacitinib 15 mg, Then 30 mg | Upadacitinib 15 mg |
|---|---|---|---|
| Week 0 | 77.4 | 69.0 | 76.6 |
| Month 12 | 74.2 | 72.4 | 72.3 |
| Month 24 | 71.0 | 75.9 | 74.5 |
| Month 36 | 71.0 | 69.0 | 70.2 |
| Month 48 | 71.0 | 69.0 | 66.0 |
| Month 60 | 67.7 | 62.1 | 68.1 |
| Month 72 | 74.2 | 69.0 | 70.2 |
| Month 84 | 71.0 | 69.0 | 70.2 |
| Month 96 | 74.2 | 65.5 | 70.2 |
Endoscopic response was defined as decrease ≥ 25% SES-CD from Baseline of Study M13-740. SES-CD was based on endoscopic findings in 5 bowel segments (Ileum, right colon, transverse colon, left colon/sigmoid, and rectum). Each item was scored 0 to 3 per segment. The sum of the scores for each endoscopic variable ranged from 0 to 15, except for stenosis, where it varied between 0 and 11; total score ranged from 0 to 56. A lower score indicated better outcome.
| percentage of participants | Upadacitinib 30 mg | Upadacitinib 15 mg, Then 30 mg | Upadacitinib 15 mg |
|---|---|---|---|
| Week 0 | 85.7 | 61.5 | 81.4 |
| Month 12 | 90.9 | 81.8 | 75.0 |
| Month 24 | 93.3 | 61.5 | 87.5 |
| Month 36 | 90.0 | 80.0 | 79.2 |
| Month 48 | 100 | 80.0 | 81.3 |
| Month 60 | 100 | 100 | 86.7 |
| Month 72 | 88.9 | 85.7 | 86.7 |
| Month 84 | 100 | 80.0 | 85.7 |
| Month 96 | 100 | 100 | 84.6 |
The IBDQ is a 32-item (ranged 1 to 7) self-report questionnaire for participants with inflammatory bowel disease to evaluate the participant-reported outcomes across 4 dimensions: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). IBDQ total Score range 32 to 224. A higher score indicated better outcome. IBDQ response was defined as an increase in IBDQ score ≥16 point from baseline of Study M13-740.
| percentage of participants | Upadacitinib 30 mg | Upadacitinib 15 mg, Then 30 mg | Upadacitinib 15 mg |
|---|---|---|---|
| Week 0 | 85.7 | 79.3 | 78.7 |
| Month 12 | 87.0 | 68.0 | 72.2 |
| Month 24 | 82.4 | 80.0 | 86.7 |
| Month 36 | 100 | 91.7 | 83.3 |
| Month 48 | 100 | 90.9 | 80.0 |
| Month 60 | 100 | 90.0 | 78.9 |
| Month 72 | 100 | 85.7 | 81.3 |
| Month 84 | 81.8 | 80.0 | 85.7 |
| Month 96 | 88.9 | 100 | 93.3 |
Remission = clinical remission and endoscopic remission. Clinical remission was average daily stool frequency ≤1.5, not worse than baseline, and average daily abdominal pain score ≤1.0 and not worse than baseline of Study M13-740. Abdominal pain was assessed using the CDAI component "abdominal pain" rated none \[0\], mild \[1\], moderate \[2\], severe \[3\] (cumulative total over the past 7 days) and multiplied by a factor of 5 as per the CDAI. Total score range 0 to 105. Endoscopic remission was defined as SES-CD ≤4 and at least 2- point reduction versus baseline of Study M13-740 and no subscore \>1 in any individual variable. SES-CD was based on endoscopic findings in 5 segments (Ileum, right colon, transverse colon, left colon/sigmoid, and rectum). Each item was scored 0 to 3 per segment. The sum of the scores for each endoscopic variable ranged from 0 to 15, except for stenosis, where it varied between 0 and 11; total score ranged from 0 to 56. A lower score indicated better outcome
| percentage of participants | Upadacitinib 30 mg | Upadacitinib 15 mg, Then 30 mg | Upadacitinib 15 mg |
|---|---|---|---|
| Month 12 | 36.4 | 33.3 | 60.0 |
| Month 24 | 42.9 | 0 | 33.3 |
| Month 36 | 33.3 | 40.0 | 66.7 |
| Month 48 | 50.0 | 40.0 | 100 |
| Month 60 | 40.0 | 50.0 | 100 |
| Month 72 | 40.0 | 50.0 | 75.0 |
| Month 84 | 75.0 | 50.0 | 100 |
| Month 96 | 40.0 | 0 | 66.7 |
Stool samples were collected for analysis of fecal calprotectin levels.
| micrograms (μg)/grams (g) | Upadacitinib 30 mg | Upadacitinib 15 mg, Then 30 mg | Upadacitinib 15 mg |
|---|---|---|---|
| Week 0 | -786.5 ± 2286.47 | -1623.9 ± 2811.99 | -1050.8 ± 1654.69 |
| Month 12 | -1237.7 ± 2441.85 | -1323.4 ± 2391.92 | -993.7 ± 1249.74 |
| Month 24 | -1633.2 ± 2682.72 | -1381.7 ± 2595.10 | -1791.9 ± 2273.29 |
| Month 36 | -1748.6 ± 1107.85 | -652.8 ± 986.68 | -1477.7 ± 1766.91 |
| Month 48 | -1271.6 ± 2062.18 | -1024.4 ± 4547.76 | -1466.6 ± 1374.09 |
| Month 60 | -2126.4 ± 2309.74 | -1225.6 ± 720.88 | -1485.2 ± 1481.70 |
| Month 72 | -1120.0 ± 1812.65 | -1501.2 ± 4874.08 | -1004.6 ± 884.68 |
| Month 84 | -1338.0 ± 1161.16 | -1451.3 ± 6321.77 | -2121.4 ± 1871.52 |
| Month 96 | -994.8 ± 1281.72 | -1049.5 ± 757.31 | -1889.4 ± 1490.62 |
| mg/L | Upadacitinib 30 mg | Upadacitinib 15 mg, Then 30 mg | Upadacitinib 15 mg |
|---|---|---|---|
| Week 0 | -12.377 ± 26.6146 | -3.954 ± 37.5299 | -11.310 ± 19.6428 |
| Month 12 | -7.901 ± 36.4956 | -9.843 ± 22.1230 | -10.757 ± 18.3601 |
| Month 24 | -14.663 ± 25.2412 | -11.406 ± 20.5222 | -9.833 ± 20.7197 |
| Month 36 | -17.782 ± 32.0214 | -13.118 ± 24.1039 | -13.069 ± 21.3781 |
| Month 48 | -19.629 ± 29.3289 | -15.104 ± 23.4962 | -11.909 ± 25.4634 |
| Month 60 | -18.125 ± 29.9039 | -9.671 ± 17.7615 | -13.324 ± 27.3104 |
| Month 72 | -18.215 ± 28.5997 | -18.624 ± 26.3939 | -14.891 ± 25.7492 |
| Month 84 | -20.361 ± 26.9004 | -26.278 ± 28.2083 | -14.704 ± 25.8847 |
| Month 96 | -20.380 ± 31.6487 | -24.517 ± 37.5441 | -8.200 ± 34.1356 |
The IBDQ is a 32-item (ranged 1 to 7) self-report questionnaire for participants with inflammatory bowel disease to evaluate the participant-reported outcomes across 4 dimensions: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). IBDQ total score range from 32 to 224. A higher score indicated better outcome.
| score on a scale | Upadacitinib 30 mg | Upadacitinib 15 mg, Then 30 mg | Upadacitinib 15 mg |
|---|---|---|---|
| Week 0 | 50.8148 ± 32.5825 | 48.9310 ± 39.6727 | 50.7367 ± 45.9608 |
| Month 12 | 59.4545 ± 29.3805 | 42.5200 ± 36.9506 | 53.2254 ± 46.4930 |
| Month 24 | 49.5294 ± 31.6882 | 61.2000 ± 40.6986 | 62.8927 ± 41.7239 |
| Month 36 | 69.3636 ± 24.5857 | 65.6667 ± 39.1020 | 67.6087 ± 40.4663 |
| Month 48 | 70.3333 ± 23.9330 | 69.1818 ± 42.8901 | 69.1053 ± 41.6958 |
| Month 60 | 68.0833 ± 27.6618 | 72.4636 ± 42.9073 | 62.6111 ± 42.8405 |
| Month 72 | 68.4722 ± 30.2596 | 74.7922 ± 49.4592 | 58.2667 ± 34.6543 |
| Month 84 | 68.8182 ± 36.5618 | 89.4000 ± 53.3976 | 59.1429 ± 44.9613 |
| Month 96 | 68.2222 ± 32.3372 | 77.2500 ± 45.7120 | 63.4667 ± 41.3087 |
The SES-CD assessed the size of mucosal ulcers, the ulcerated surface, the endoscopic extension and the presence of stenosis. SES-CD was based on endoscopic findings in 5 bowel segments (Ileum, right colon, transverse colon, left colon/sigmoid, and rectum). Each item was scored 0 to 3 per segment. The sum of the scores for each endoscopic variable ranged from 0 to 15, except for stenosis, where it varied between 0 and 11; total score ranged from 0 to 56. A lower score indicated better outcome. Endoscopic remission was defined as SES-CD ≤4 and at least two-point reduction versus Baseline of Study M13-740 and no subscore \>1 in any individual variable.
| score on a scale | Upadacitinib 30 mg | Upadacitinib 15 mg, Then 30 mg | Upadacitinib 15 mg |
|---|---|---|---|
| Week 0 | -10.0 ± 8.15 | -6.8 ± 10.33 | -8.9 ± 7.81 |
| Month 12 | -14.0 ± 8.63 | -8.4 ± 11.02 | -9.0 ± 9.59 |
| Month 24 | -14.9 ± 9.96 | -6.4 ± 12.29 | -9.3 ± 7.06 |
| Month 36 | -17.3 ± 9.67 | -8.7 ± 12.18 | -11.8 ± 9.75 |
| Month 48 | -18.2 ± 10.30 | -9.5 ± 9.64 | -11.6 ± 9.37 |
| Month 60 | -19.4 ± 8.68 | -15.6 ± 9.15 | -12.8 ± 9.15 |
| Month 72 | -16.4 ± 10.32 | -10.4 ± 8.83 | -11.5 ± 10.03 |
| Month 84 | -19.2 ± 9.33 | -8.2 ± 10.26 | -12.4 ± 9.87 |
| Month 96 | -19.0 ± 8.72 | -13.7 ± 9.87 | -11.1 ± 9.24 |
Collected over From first dose of study drug through 96 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Upadacitinib 30 mg | 0/31 (0%) | 9/31 (29%) | 31/31 (100%) |
| Upadacitinib 15 mg, Then 30 mg | 0/29 (0%) | 7/29 (24.1%) | 27/29 (93.1%) |
| Upadacitinib 15 mg | 1/47 (2.1%) | 15/47 (31.9%) | 41/47 (87.2%) |
| Event | Upadacitinib 30 mg | Upadacitinib 15 mg, Then 30 mg | Upadacitinib 15 mg |
|---|---|---|---|
| CROHN'S DISEASEGASTROINTESTINAL DISORDERS | 4/31 | 4/29 | 3/47 |
| ANAL ABSCESSINFECTIONS AND INFESTATIONS | 3/31 | 0/29 | 0/47 |
| ILEUSGASTROINTESTINAL DISORDERS | 0/31 | 1/29 | 0/47 |
| LARGE INTESTINE PERFORATIONGASTROINTESTINAL DISORDERS | 0/31 | 1/29 | 0/47 |
| SMALL INTESTINAL OBSTRUCTIONGASTROINTESTINAL DISORDERS | 1/31 | 1/29 | 0/47 |
| CHOLELITHIASISHEPATOBILIARY DISORDERS | 0/31 | 1/29 | 0/47 |
| DRUG-INDUCED LIVER INJURYHEPATOBILIARY DISORDERS | 0/31 | 1/29 | 0/47 |
| ABDOMINAL ABSCESSINFECTIONS AND INFESTATIONS | 1/31 | 1/29 | 0/47 |
| GASTROENTERITIS VIRALINFECTIONS AND INFESTATIONS | 0/31 | 1/29 | 1/47 |
| TYPE 2 DIABETES MELLITUSMETABOLISM AND NUTRITION DISORDERS | 0/31 | 1/29 | 0/47 |
| Event | Upadacitinib 30 mg | Upadacitinib 15 mg, Then 30 mg | Upadacitinib 15 mg |
|---|---|---|---|
| CROHN'S DISEASEGASTROINTESTINAL DISORDERS | 9/31 | 13/29 | 9/47 |
| COVID-19INFECTIONS AND INFESTATIONS | 7/31 | 7/29 | 16/47 |
| NASOPHARYNGITISINFECTIONS AND INFESTATIONS | 10/31 | 5/29 | 10/47 |
| UPPER RESPIRATORY TRACT INFECTIONINFECTIONS AND INFESTATIONS | 8/31 | 6/29 | 8/47 |
| ARTHRALGIAMUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS | 7/31 | 7/29 | 7/47 |
| FATIGUEGENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | 7/31 | 6/29 | 9/47 |
| BLOOD CREATINE PHOSPHOKINASE INCREASEDINVESTIGATIONS | 7/31 | 5/29 | 8/47 |
| ACNESKIN AND SUBCUTANEOUS TISSUE DISORDERS | 7/31 | 1/29 | 3/47 |
| HYPERTENSIONVASCULAR DISORDERS | 7/31 | 2/29 | 4/47 |
| URINARY TRACT INFECTIONINFECTIONS AND INFESTATIONS | 5/31 | 6/29 | 9/47 |
Intent-to-Treat (ITT) Population: all participants who enrolled into the study and received at least 1 dose of study drug.
| Age, Continuous(years) | Upadacitinib 30 mg | Upadacitinib 15 mg, Then 30 mg | Upadacitinib 15 mg | Total |
|---|---|---|---|---|
| Mean | 38.4 ± 13.55 | 41.0 ± 14.42 | 40.8 ± 11.65 | 40.2 ± 12.92 |
| Sex: Female, Male(Participants) | Upadacitinib 30 mg | Upadacitinib 15 mg, Then 30 mg | Upadacitinib 15 mg | Total |
|---|---|---|---|---|
| Female | 17 | 14 | 25 | 56 |
| Male | 14 | 15 | 22 | 51 |
| Ethnicity (NIH/OMB)(Participants) | Upadacitinib 30 mg | Upadacitinib 15 mg, Then 30 mg | Upadacitinib 15 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 2 | 3 | 4 | 9 |
| Not Hispanic or Latino | 29 | 26 | 43 | 98 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Upadacitinib 30 mg | Upadacitinib 15 mg, Then 30 mg | Upadacitinib 15 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 1 | 2 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 1 | 3 | 7 |
| White | 27 | 26 | 43 | 96 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from May 2016 to primary completion in Jul 2025, 110 months.
Results were first posted in Aug 2026, 1 year after primary completion.
Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 110 months is above that.
Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Upadacitinib